Debbie Robbrecht

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Braña, Geoffrey I. Shapiro, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2021 · 67 citations

Tumor Biology, Molecular Pharmacology, Dose Finding Study +14

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Alwin Krämer, Tilmann Bochtler, Chantal Pauli et al. · The Lancet · 2024 · 58 citations · Full text

Therapy Versus Chemotherapy, Health Sciences, Medicine +11

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

Reetta Virtakoivu, Jenna H. Rannikko, Miro Viitala et al. · Clinical Cancer Research · 2021 · 51 citations · Full text

Association of anti-heart antibodies and circulating immune complexes in the post-pericardiotomy syndrome.

Ivan De Scheerder, Denis Wulfrank, L. Van Renterghem et al. · PubMed · 1984 · 44 citations · Full text

Heart Failure, Cardiac Anaesthesia, Immunology +18

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Morten Mau‐Sørensen, Willeke Ros, María E. Rodríguez-Ruiz et al. · Journal of Clinical Oncology · 2018 · 40 citations

Engineered Variant, Immunology, Outpatient Setting +23